PharmacoEconomics & Outcomes News 604 - 29 May 2010

Dexlansoprazole provides long-term QOL benefits

Dexlansoprazole significantly improves QOL andsymptom severity in patients with gastro-oesophagealreflux disease (GORD), according to a study conductedby researchers associated with Takeda PharmaceuticalsNorth America and Takeda Global Research &Development Center. "These improvements weresustained throughout the 12-month treatment period",they say.

Patients (n = 313) with symptomatic non-erosiveGORD (who had completed a 4-week study on placebo,or dexlansoprazole 60mg or 90mg) receiveddexlansoprazole* 60mg or 90mg once daily for a furtheryear. Patients completed the Patient Assessment ofUpper Gastrointestinal Disorders-Quality of Life (PAGI-QOL) and PAGI-Symptoms Severity Index instrumentsat baseline and the end of the 4-week study, as well as atmonths 1, 3, 6, 9, and 12 of the 1-year study.

Patients who had previously receiveddexlansoprazole, experienced significant improvementsfrom baseline in PAGI-QOL total score and significantreductions from baseline in symptom severity at the endof the 4-week study, which was sustained at each visit inthe 1-year study. By the end of the first month in the1-year study, patients who had previously receivedplacebo had similar improvements in both their QOLand symptom scores to patients who had previouslyreceived dexlansoprazole.* modified-release formulation

Mody R, et al. Long-Term Benefits of Dexlansoprazole MR on Quality of Life andSymptom Severity Among Gastroesophageal Reflux Disease (GERD) Patients.2010 Digestive Disease Week : abstr. W1121, 1 May 2010. Available from: URL:http://www.ddw.org/wmspage.cfm?parm1=679 803015887

1

PharmacoEconomics & Outcomes News 29 May 2010 No. 6041173-5503/10/0604-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved